Ovid Board Member's Stock Option Grant Signals Long-term Confidence in Biotech Firm

Rhea-AI Filing Summary

Insider Trading Alert: Barbara Gayle Duncan, Director at Ovid Therapeutics (OVID), received a stock option grant on February 20, 2025. The transaction details include:

• Granted 45,000 stock options to purchase common stock
• Exercise price set at $0.57 per share
• Options will vest fully on February 20, 2026, contingent on continuous service
• Options expire on February 19, 2035

This Form 4 filing, reported by the director's attorney-in-fact Jason Minio on June 18, 2025, represents a standard equity compensation grant for board service. The relatively low exercise price and one-year cliff vesting schedule suggest this is part of the company's regular director compensation program.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Duncan Barbara Gayle

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	45,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 45,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duncan Barbara Gayle

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.57	02/20/2025		A		45,000		(1)	02/19/2035	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Jason Minio, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Barbara Duncan receive from OVID on February 20, 2025?

Barbara Duncan received 45,000 stock options with an exercise price of $0.57 per share. These options were granted on February 20, 2025, and will expire on February 19, 2035.

When do Barbara Duncan's OVID stock options vest?

The stock options will vest in full on February 20, 2026, subject to Barbara Duncan's continuous service through the vesting date.

What is Barbara Duncan's role at OVID Therapeutics?

According to the Form 4 filing, Barbara Duncan serves as a Director of Ovid Therapeutics Inc. (OVID).

What was the exercise price of OVID stock options granted to Barbara Duncan?

The stock options were granted with an exercise price of $0.57 per share.

How many OVID derivative securities does Barbara Duncan own after this transaction?

Following this transaction, Barbara Duncan beneficially owns 45,000 derivative securities (stock options) of OVID directly.